[Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children]

Abstract

Neutropenia is the most often side effect during antineoplastic treatment. In this article current recommendations for clinical applications of granulocyte and granulocyto-macrophage hematopoietic factors and possibility of protection of neutropenia, and its serious complications in pediatric oncology are presented.